FLT3 and acute lymphoblastic leukemia: (32) revealed that in B-ALL, patients with RAS pathway mutations (NRAS, KRAS, and FLT3) are more chemoresistant, and NRAS or KRAS mutations are common genetic abnormalities in relapsed ALL and are associated with poor prognosis.